For decades, tobacco control policies have been built around a straightforward premise: products containing tobacco should be regulated as tobacco products. This approach made sense when cigarettes, cigars, and smokeless tobacco dominated the market. Today, however, the nicotine landscape has changed significantly. A growing range of smoke-free products, including nicotine pouches, electronic cigarettes, heated tobacco…
The United Kingdom’s Tobacco and Vapes Act marks one of the most significant tobacco control reforms in a generation. By introducing a “smoke-free generation” policy and strengthening the regulation of tobacco and vaping products, the legislation establishes an ambitious framework for reducing smoking prevalence and protecting future generations. But passing legislation is only the beginning.…
For decades, nicotine regulation has been built upon laboratory science, toxicological assessments, and clinical research. These forms of evidence remain indispensable for understanding product chemistry, biological mechanisms, and potential health effects. Yet as smoke-free nicotine products continue to evolve, regulators are increasingly recognising that scientific evidence alone does not always explain how products perform in…
Why Evidence Matters in Public Health Communication A recent article published by Stanford Medicine, “Nicotine Pouches: The Tobacco Industry’s Latest Ploy?”, raises legitimate concerns about nicotine addiction and youth uptake. These are important issues that deserve serious attention and are shared concerns across the public health community. However, effective public health communication should present the…
From 1 August 2026, Finland will complete one of Europe’s most comprehensive regulatory frameworks for nicotine pouches as standardized plain packaging requirements become fully mandatory. The measures represent the final stage of amendments to Finland’s Tobacco Act that have progressively tightened controls on nicotine pouches since August 2025. For GINN, Finland’s approach is significant not…
As nicotine pouches continue to emerge within tobacco harm reduction discussions, policymakers are increasingly faced with a fundamental question: how should the health risks of these products be assessed? Public debate often reduces the issue to a simple question of whether nicotine pouches are “safe” or “unsafe.” While understandable, this framing overlooks how modern toxicology…
Public health policy depends on informed decision-making. Whether developing regulation, advising patients, or supporting smoking cessation, decisions are only as effective as the information on which they are based. When scientific evidence is misunderstood, selectively interpreted, or communicated without appropriate context, the consequences can extend beyond public debate and influence individual health behaviours. This challenge…
Smoking during pregnancy remains one of the most significant preventable causes of adverse maternal and infant health outcomes worldwide. It increases the risk of miscarriage, placental complications, preterm birth, low birth weight, stillbirth, and sudden infant death syndrome, while also contributing to long-term health consequences for both mother and child. For healthcare professionals, the objective…
The rapid emergence of oral nicotine pouches has presented policymakers with a familiar challenge. Innovation is moving faster than legislation, forcing regulators to determine how new products fit within legal frameworks that were largely designed for traditional tobacco products decades ago. A recent editorial published in Addiction, “Novel Product, Familiar Challenges: Navigating Uncertainty in Oral…
Every year, the United States Food and Drug Administration’s National Youth Tobacco Survey (NYTS) provides one of the most closely watched snapshots of tobacco and nicotine use among young people. The survey plays an important role in informing regulatory discussions not only in the United States but also globally, as policymakers increasingly look to youth…